Stoke Therapeutics: A Pivotal Moment For This RNA Pioneer

Stoke Therapeutics (NASDAQ: NASDAQ: STOK ) develops RNA-based treatments for severe neurological and ophthalmic disorders. Although the stock is volatile, its unique strategy for restoring protein expression in haploinsufficient diseases makes it a possible long-term winner. Its lead candidate, zorevunersen, is nearingI have a strong inclination towards high-growth companies, often treading in sectors poised for exponential expansion. My expertise lies in understanding and investing in disruptive technologi ...